Edwards Lifesciences (NYSE: EW) stock rises after Stifel upgrades to Buy, citing potential for TAVR growth acceleration in 2025. Read more here.

Earlie Smith experienced an aortic dissection. Months later, her brother, Larry Smith, also had one. The same doctor helped ...

Edwards Lifesciences shares rise as analyst upgrades stock, citing TAVR growth, margin expansion, and strategic business ...

The Heart Valve Devices Market is driven by advancements in aortic, mitral, tricuspid, and pulmonary valve technologies. It ...

We came across a bullish thesis on Edwards Lifesciences Corporation (EW) on Substack by Natan. In this article, we will ...

Middle-aged adults who need an aortic valve replacement fare better with mechanical devices than with the valves made from animal tissues that they currently most often receive, U.S. researchers ...

Although no medical treatment is yet approved, doxycycline has been shown to greatly reduce aortic aneurysm growth in animal models and has been shown to slow growth in several small clinical trials.

Aneurysm occurs when a blood vessel weakens and bulges If this blood vessel is ruptured it can lead to severe internal ...

During a routine test, Johnny's middle school nurse discovered his severe scoliosis, a prevalent symptom of Marfan. This unexpectedly set his family on a path to uncover his underlying diagnosis at ...

David Correa Allied Market Research + + 1 800-792-5285 email us here Visit us on social media: Facebook X LinkedIn YouTube ...

Amavita has started using AISAP’s AI-powered POCUS diagnostic in community settings for aortic stenosis screening.

Stifel analyst Rick Wise upgraded Edwards Lifesciences (EW) to Buy from Hold with a price target of $90, up from $75. The firm said that TAVR, ...